Pacmilimab Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5752-10mg

Add to Compare

Be the first to review this product

Pacmilimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG4 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of pacmilimab (CX-072), an investigational anti-PD-L1 antibody, supplied strictly for research use only. It is a human IgG4 (kappa) built around the PD-L1 target to reproduce the antigen-binding behavior of the originator, and it is not the clinical drug and is not intended for human or veterinary use. The originator is notable as a conditionally activated "Probody" prodrug in which a masking peptide restricts binding until tumor-associated proteases remove it; this research-grade analog is offered as a standard unmasked antibody format for straightforward benchtop use unless otherwise specified. It is useful as a benchmarking reagent and positive/isotype-matched control in PD-L1 binding, blockade, and checkpoint-assay development, for comparison against other anti-PD-L1 analogs, and for antibody-engineering, ADCC/ADC-development, and preclinical model work. Available at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk mg-to-gram quantities to support screening, assay standardization, and scale-dependent studies. Guidance for ichorbio to review. PD-L1 (Programmed Death-Ligand 1; also CD274 or B7-H1; UniProt Q9NZQ7) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It is expressed on many tumor cells, antigen-presenting cells, and various stromal and epithelial tissues, and is upregulated by inflammatory signals such as interferon-gamma. PD-L1 binds the inhibitory receptor PD-1 (PDCD1) on activated T cells, delivering a co-inhibitory signal that dampens T-cell receptor signaling, cytokine production, and effector function. It also engages CD80 (B7-1). Through these interactions PD-L1 contributes to peripheral immune tolerance and limits chronic inflammation, but tumors co-opt this axis to evade immune attack. Blocking PD-L1's engagement of PD-1 releases this brake and can restore anti-tumor T-cell activity, which is the rationale underlying PD-L1-directed checkpoint agents.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.